NEWS & PERSPECTIVES
Psychedelics News
Curated updates on microdosing, research, policy, and community.
The latest
MAPS Announces Agreement with UAB
MAPS can now share we have finalized a clinical trial agreement with the University of Alabama, Birmingham, making UAB the first official site for the MJP2 study of inhaled cannabis in the treatment of PTSD in U.S. mi...
Immune signals may help predict responses to therapies for difficult-to-treat depression
In a new study, researchers from The University of Texas MD Anderson Cancer Center have uncovered insights that may help explain how rapid-acting antidepressants, such as ketamine and psychedelics, can reduce symptoms...
The Personalities Psychedelics Reward (And Punish)
Welcome to The Psychedelic Blog.
So, the Medicine Introduced You to Your Soulmate. Now What?
Meeting your soulmate in ceremony was the mystical part, but how do you make it last afterwards? [...] Read More... The post So, the Medicine Introduced You to Your Soulmate. Now What? appeared first on DoubleBlind Mag.
SciSparc: Subsidiary NeuroThera Labs' Quantum Platform Demonstrates Complete End-to-End Hybrid Quantum-Classical Workflow for Clinical Data Analytics
TEL AVIV, Israel, July 31, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage…
The Power of Story, Myth, and Belief with John O’Connor
Author John O’Connor explores the mystical legacy of Terence McKenna to look beyond the "cheerleaderism" of the modern psychedelic renaissance. By journeying from the Amazon to American subcultures, O’Connor reveals h...
Psilocybin Trial in Veterans With Treatment-Resistant PTSD Reports 75% Remission at One Month
Nine of twelve veterans with severe, treatment-resistant PTSD no longer met diagnostic criteria a month after two doses of psilocybin. The trial was designed to test safety, not efficacy, and the most interesting resu...
Psychedelic Policy Briefing: Week of July 27th, 2026
The House voted to extend the Pentagon's psychedelic research program through 2033, then blocked a Right to Try expansion that would have let doctors administer Schedule I drugs to patients with life-threatening condi...
Definium Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026
NEW YORK, July 30, 2026--Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes…
Neuroscientists just upended a core assumption about how psychedelics alter brain function
New brain scans show that drugs like LSD, psilocybin, and MDMA reliably reduce the upward flow of information into a core brain network. This surprising shift offers a biological explanation for their psychological ri...
For veterans with severe PTSD, psilocybin-assisted therapy may help
The first U.S. clinical trial of psilocybin-assisted therapy in veterans with PTSD who got no relief from conventional treatments found that the protocol was safe, with no serious adverse events or increases in suicid...
Quantum BioPharma Announces Closing of Debt Settlement
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, July 30, 2026…
Safety, feasibility, and preliminary clinical outcomes of psilocybin-assisted therapy for veterans with severe, treatment-resistant PTSD: an open-label pilot clinical trial
This open-label pilot clinical trial (n=12) tested psilocybin-assisted therapy in U.S. military veterans with severe, treatment-resistant PTSD and found no serious side effects or increase in suicidal thoughts, while ...
Is Getting High Off of Banana Peels a Thing?
Congress really did try to regulate banana peels. [...] Read More... The post Is Getting High Off of Banana Peels a Thing? appeared first on DoubleBlind Mag.
SciSparc: Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P 500 company
TEL AVIV, Israel, July 29, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage…